Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24816122 | 0.78 | NPC1 (0.47) | NPC1RAB9AMAPTPPARGNTRK1 | |
| SCHEMBL23638356 | 0.78 | NPC1 (0.47) | PDE10ANPC1RAB9AMAPTPPARG | |
| SCHEMBL23638355 | 0.74 | NPC1 (0.44) | NPC1RAB9AMAPTPPARGNTRK1 | |
| SCHEMBL23638515 | 0.74 | RAB9A (0.49) | NPC1RAB9AMAPTPPARGNTRK1 | |
| SCHEMBL13777230 | 0.74 | RAB9A (0.49) | NPC1RAB9AMAPTPPARGSMN1; SMN2 | |
| SCHEMBL24329944 | 0.74 | NPC1 (0.49) | NPC1RAB9AMAPTPPARGIKBKB | |
| SCHEMBL23638381 | 0.74 | MAPT (0.47) | PDE10ANPC1RAB9AMAPTPPARG | |
| SCHEMBL24816119 | 0.72 | MAPT (0.53) | NPC1RAB9AMAPTPPARGSMN1; SMN2 | |
| SCHEMBL23638286 | 0.72 | NPC1 (0.47) | NPC1RAB9AMAPTPPARGSMN1; SMN2 | |
| SCHEMBL25539217 | 0.72 | TP53 (0.50) | NPC1RAB9AMAPTPPARGNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165846-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165846-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PDE10A 81/4885NPC1 1541/4885RAB9A 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.